A practical reference on tuftsin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-23. Anything still debated is marked as such rather than presented as settled.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
| Property | Value | Notes |
|---|---|---|
| Route studied | Intranasal | Predominant route in published reports |
| Circulation stability | Short, minutes scale | Peptidases cleave it; the tail slows the process |
| Analytical method | RP-HPLC with mass spectrometry | Used for identity and purity assessment |
| Reported outcome domains | Anxiety and cognitive measures | Derived from small, mostly regional trials |
| Regulatory status | Marketed in Russia | Availability outside that market is limited |
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Only six years later, Hurricane Hattie struck the central coastal area of the country, with winds in excess of 300 km/h (185 mph) and 4 m (13 ft) storm tides. The devastation of Belize City for the second time in thirty years prompted the relocation of the capital some 80 kilometres (50 mi) inland to the planned city of Belmopan. In 1978, Hurricane Greta caused more than US$25 million in damage along the southern coast. In 2000, Hurricane Keith, the wettest tropical cyclone in the nation's record, stalled, and hit the nation as a Category 4 storm on 1 October, causing 19 deaths and at least $280 million in damage. Soon after, on 9 October 2001, Hurricane Iris made landfall at Monkey River Town as a 235 km/h (145 mph) Category 4 storm. The storm demolished most of the homes in the village, and destroyed the banana crop. In 2007, Hurricane Dean made landfall as a Category 5 storm only 40 km (25 mi) north of the Belize–Mexico border. Dean caused extensive damage in northern Belize. In 2010, Belize was directly affected by the Category 2 Hurricane Richard, which made landfall approximately 32 kilometres (20 mi) south-southeast of Belize City at around 00:45 UTC on 25 October 2010. The storm moved inland towards Belmopan, causing estimated damage of BZ$33.8 million ($17.4 million 2010 USD), primarily from damage to crops and housing. The most recent hurricane to make landfall in Belize was Hurricane Lisa in 2022. Extreme weather events, such as hurricanes and floods, have become more frequent and intense due to climate change.
When the median nerve is compressed, it will conduct more slowly than normal and more slowly than other nerves. Nerve compression results in damage to the myelin sheath and manifests as delayed latencies and slowed conduction velocities. Electrodiagnosis rests upon demonstrating impaired median nerve conduction across the carpal tunnel in the context of normal conduction elsewhere. It is often stated that normal electrodiagnostic studies do not preclude the diagnosis of carpal tunnel syndrome. The rationale for this is that a threshold of neuropathy must be reached before study results become abnormal, and also that threshold values for abnormality vary. Others contend that idiopathic median neuropathy at the carpal tunnel with normal electrodiagnostic tests would represent very, very mild neuropathy that would be best managed as a normal median nerve. Even more important, notable symptoms with mild disease are strongly associated with unhelpful thoughts and symptoms of worry and despair. Notable CTS should remind clinicians to always consider the whole person, including their mindset and circumstances, in strategies to help people get and stay healthy. A report published by the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), the American Academy of Physical Medicine and Rehabilitation (AAPM&R), and the American Academy of Neurology defines practice parameters, standards, and guidelines for electrodiagnostic testing studies of CTS based on an extensive critical literature review.
== Enterprises == SIP Animation, originally Saban International Paris, France based TV production company Société genevoise d'instruments de physique, Swiss manufacturer of precision machinery Société Immobilière Publique, a state-owned housing company in Burundi Società Italiana per l'Esercizio Telefonico (originally Società Idroelettrica Piemontese), the former name of Telecom Italia Selznick International Pictures, a defunct film studio
==== Netherlands ==== In the Netherlands, the Opium Law classifies all barbiturates as List II drugs, with the exception of secobarbital, which is on List I. There is a small group of List II drugs for which physicians have to write the prescriptions according to the same, tougher guidelines as those for List I drugs (writing the prescription in full in letters, listing the patients name, and have to contain the name and initials, address, city and telephone number of the licensed prescriber issuing the prescriptions, as well as the name and initials, address and city of the person the prescription is issued to). Among that group of drugs are the barbiturates amobarbital, butalbital, cyclobarbital, and pentobarbital.
Sources: en.wikipedia.org
In 2016, Singapore students topped both the Programme for International Student Assessment (PISA) and the Trends in International Mathematics and Science Study (TIMSS). In the 2016 EF English Proficiency Index taken in 72 countries, Singapore placed 6th and has been the only Asian country in the top 10.
==== Fatal outcomes in case reports ==== A 2017 case report details the severe, prolonged episode of drug-induced parkinsonism in a 68‑year‑old man in the United States that ultimately led to his death roughly five months after receiving two injections of paliperidone palmitate (234 mg followed one week later by 156 mg). The authors state that "practitioners should be cognizant of the potential long‑term consequences of paliperidone LAI." A 47‑year‑old man (Japan, 2017) developed acute and persistent circulatory failure after receiving paliperidone palmitate injections. Despite surgical removal of the hip tissue suspected of containing the paliperidone palmitate depot, he died of multiple organ failure. When examining the removed tissue, it seemed that paliperidone palmitate was not present, and Janssen, the drug manufacturer, does not recommend this approach since it is practically impossible to locate the depot of paliperidone. The optimal treatment of long‐acting injectable (LAI) antipsychotic poisonings is unknown. In 2019, it was reported that a 33-year-old man in France was found dead in his room at his parents' home after receiving a single 819 mg injection of Trevicta (paliperidone palmitate three‑monthly formulation). Toxicological analysis of femoral blood revealed paliperidone at 240 μg/L; no other substance was detected. The authors concluded that paliperidone poisoning was the highly likely cause of death.
==== Development of oral antivirals ==== In November 2021, Pfizer launched a new COVID-19 oral antivirus treatment known as Paxlovid. In January 2022, the Pfizer CEO Albert Bourla confirmed that the trial results of a fourth dose were pending until March 2022. He said that the firm was setting up a collaboration to develop an anti-COVID pill treatment along with a French company, Novasep. He also said the COVID vaccine was "safe and efficient" for children. In May 2022, reports emerged of patients experiencing "rebound" symptoms after completing a five-day course of Paxlovid. The FDA responded by announcing they had performed additional analyses of the drug's clinical trial data, and decided against changing its recommendations. U.S. President Joe Biden and Dr. Anthony Fauci were both reported to experience this rebound syndrome in the months that followed, while continuing to recommend the drug for those who may benefit from it.
=== Regulatory approval === Lurasidone was approved in the United States for the treatment of schizophrenia in October 2010 and for the treatment of depressive episodes associated with bipolar I disorder in June 2013. In 2015, lurasidone was studied for major depressive disorder with mixed features in a randomized trial and had a positive result, however it did not receive an FDA indication for it. In 2017, the FDA approved lurasidone for schizophrenia in adolescents age 13-17. In 2018, lurasidone was approved for bipolar depression in children and adolescents age 10-17. It received regulatory approval in the United Kingdom in September 2014. In October 2014, NHS Scotland advised use of lurasidone for schizophrenic adults who have not seen improvements with previous antipsychotics due to problems that arise from weight gain or changes in metabolic pathways when taking other medications. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for it in January 2014, and it was approved for medical use by the EMA in March 2014. It was launched in Canada for the treatment of schizophrenia in September 2012, Health Canada giving their Summary Basis of Decision (SBD) as favourable on 15 October 2012. The European Commission has granted a marketing authorization for once-daily oral lurasidone for the treatment of schizophrenia in adults. It is approved for use in the EU. Generic versions of lurasidone were approved for use in the United States in January 2019 and became available in 2023.
=== Determining the time of divergence in phylogenetic trees === The molecular clock hypothesis predicts that the rate of amino acid substitution in a particular protein will be approximately constant over time, though this rate may vary between protein families. This suggests that the number of mutations per amino acid in a protein increases approximately linearly with time. Determining the time at which two proteins diverged is an important task in phylogenetics. Fossil records are often used to establish the position of events on the timeline of the Earth's evolutionary history, but the application of this source is limited. However, if the rate at which the molecular clock of protein family ticks — that is, the rate at which the number of mutations per amino acid increases — is known, then knowing this number of mutations would allow the date of divergence to be found. Suppose the date of divergence for two related proteins, taken from organisms living today, is sought. The two proteins have both been accumulating accepted mutations since the date of divergence, and so the total number of mutations per amino acid separating them is approximately twice that which separates them from their common ancestor. If a range of PAM matrices are used to align two proteins that are known to be related, then the value of
Sources: en.wikipedia.org
Other minor differences occurred along with the facelift. The range was replaced in 1980, however, the station wagon models continued in production until 1986. The FA4-series Familia/323 was available in several body variants:
American biochemist at the University of Medicine and Dentistry of New Jersey, known for his discovery of sodium-glucose cotransport. Francis Crick FRS (1916–2004). British molecular biologist and neuroscientist at the University of Cambridge and the Salk Institute, noted for proposing the double helical structure of DNA. Foreign associate Natl. Acad. Sci. USA. Pedro Cuatrecasas (1936–2025). American biochemist at UC San Diego, known for the development of affinity chromatography. Member Natl. Acad. Sci. USA. Richard D. Cummings (20th–21st century). American biologist at Harvard, known for studying pathways of glycoconjugate biosynthesis and alterations in biosynthesis in human and animal diseases. Anthony Czarnik (b. 1957). American chemist and inventor known for pioneering studies in the field of fluorescent chemosensors.
=== Age === Age estimation attempts to determine the skeletal/biological age-at-death. The primary assumption is that an individual's skeletal age is closely associated with their chronological age. Age estimation can be based on patterns of growth and development or degenerative changes in the skeleton. A variety of skeletal series methods to assess these types of changes have been developed. For instance, in children age is typically estimated by assessing dental development, ossification and fusion of specific skeletal elements, or long bone length. For children, different teeth erupt from the gums serially are the most reliable for telling a child's age. However, fully developed teeth are less indicative. In adults, degenerative changes to the pubic symphysis, the auricular surface of the ilium, the sternal end of the 4th rib, and dental attrition are commonly used to estimate skeletal age. Until the age of about 30, human bones keep growing. Different bones fuse at different points of growth. This development can vary across individuals. Wear and tear on bones further complicates age estimates. Often, estimates are limited to 'young' (20–35 years), 'middle' (35–50 years), or 'old' (50+ years).
=== Funding trajectory === Since 1999, the division's funding increased more than six-fold. By 2012, OAM and NCCAM spent a cumulative $1.6 billion in grant funding. Between 1999 and 2009, NCCAM supported approximately 50% of the National Cancer Institute spending on CAM, with the total amount spent on CAM during that time frame $2.856 billion. The NCCIH budget for 2005 was $123 million. For fiscal year 2009 (ending September 30, 2009), it was $122 million. The NIH has also conducted research in alternative medicine at the National Cancer Institute by the Office of Cancer Complementary and Alternative Medicine which, in 2009, had the same $122 million budget as NCCIH. For FY 2009; NIH's total budget was about $29 billion. The NCCIH budget for 2015 was $124.1 million. They requested a $3,459,000 funding increase for their 2016 budget. By FY2023, the NCCIH budget had grown to approximately $170 million annually. The FY2026 President's Budget proposed eliminating NCCIH entirely, but Congress rejected the proposal and maintained NCCIH funding at the FY2025 level.
Sources: en.wikipedia.org
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.
Intranasal delivery is the route described in most published work. It is used because the peptide is degraded quickly once it reaches circulation. Direct evidence of brain penetration in humans is lacking.
Most trials are small, regionally concentrated, and often lack rigorous blinding or placebo control. Independent replication is limited. Reviews in English generally rate the evidence as preliminary.
Purity is usually reported as an HPLC area percentage, most often measured at 214 nm. Identity is confirmed separately by mass spectrometry. A certificate of analysis should state both the method and the observed value.